GANX stock sentiment todayGain Therapeutics Inc
Sentiment verdict
Gossip first, financials second — COLD at 75% confidence.
Last updated · cached analysis, refreshes periodically
GANX
Gain Therapeutics IncA high-risk biotech micro-cap facing a liquidity crunch and binary clinical outcomes in the crowded Parkinson's space.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for GANX. Not financial advice.
Price · last 12 months
Gossip
Market sentiment is currently suppressed by a lack of near-term catalysts and heavy selling pressure following recent equity offerings. While there is niche excitement regarding their Magellan platform for computational drug discovery, the narrative is dominated by 'wait-and-see' regarding Phase 1 data for GT-02287.
- ·Clinical data dependency for Parkinson's candidate
- ·Low trading volume and institutional exit risks
- ·Platform technology validation vs. actual drug efficacy
Financial
Classic pre-revenue biotech profile with a dwindling cash runway. The company operates at a net loss with significant R&D spend, necessitating frequent dilutive capital raises to fund late-stage clinical trials.
- ·Negative ROE and ROA reflecting developmental stage
- ·Cash runway estimated to be less than 12 months without further financing
- ·Micro-cap status leads to high volatility and bid-ask spreads
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High probability of shareholder dilution through secondary offerings
- ·Clinical failure risk for lead candidate GT-02287
- ·Extreme price volatility due to low market capitalization
Peer temperature
How direct competitors stack up against GANX right now.
- NEUTRALPRTAProthena Corporation
Stronger balance sheet and more advanced clinical pipeline in neurodegeneration with major pharma partnerships.
See full analysis → - NEUTRALSNCEScience 37 Holdings
Similarly micro-cap but operates a less capital-intensive clinical research model compared to GANX's drug discovery.
See full analysis → - NEUTRALABBVAbbVie Inc.
De-risked investment with diversified revenue and established Parkinson's treatments (Duopa) compared to GANX's speculative phase.
See full analysis →
- GANX-34.7%
- PRTA+1.1%
- SNCE—
- ABBV+12.7%
Analyst price target
Consensus average of 5 analysts · median 8.00
Source: StockAnalysis.com · updated 2026-10-05
AI-generated analysis for informational purposes only. Not financial advice.